Hsbc Holdings PLC Grows Stake in Henry Schein, Inc. (NASDAQ:HSIC)

Hsbc Holdings PLC increased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 177,720 shares of the company’s stock after purchasing an additional 5,207 shares during the quarter. Hsbc Holdings PLC owned approximately 0.14% of Henry Schein worth $11,394,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Empirical Finance LLC boosted its stake in Henry Schein by 3.5% during the first quarter. Empirical Finance LLC now owns 4,764 shares of the company’s stock valued at $360,000 after buying an additional 160 shares during the last quarter. Covestor Ltd lifted its stake in Henry Schein by 12.8% in the first quarter. Covestor Ltd now owns 1,511 shares of the company’s stock worth $114,000 after acquiring an additional 171 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Henry Schein by 3.2% during the second quarter. Sequoia Financial Advisors LLC now owns 5,680 shares of the company’s stock valued at $364,000 after purchasing an additional 176 shares in the last quarter. Wahed Invest LLC boosted its position in Henry Schein by 9.2% during the 4th quarter. Wahed Invest LLC now owns 2,222 shares of the company’s stock valued at $168,000 after acquiring an additional 187 shares in the last quarter. Finally, Crossmark Global Holdings Inc. grew its stake in Henry Schein by 1.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 13,090 shares of the company’s stock valued at $991,000 after purchasing an additional 197 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Henry Schein stock opened at $71.63 on Tuesday. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46. The stock has a market cap of $9.17 billion, a P/E ratio of 24.20, a PEG ratio of 1.88 and a beta of 0.86. The company has a 50-day moving average price of $70.00 and a 200 day moving average price of $70.29. Henry Schein, Inc. has a 12-month low of $60.01 and a 12-month high of $82.63.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. The firm had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.27 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.31 earnings per share. Sell-side analysts anticipate that Henry Schein, Inc. will post 4.75 earnings per share for the current year.

Insider Transactions at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the sale, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HSIC shares. UBS Group reduced their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Barrington Research reiterated an “outperform” rating and set a $82.00 price objective on shares of Henry Schein in a research note on Friday. JPMorgan Chase & Co. decreased their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Piper Sandler reiterated an “overweight” rating and set a $86.00 price target on shares of Henry Schein in a research report on Friday, June 21st. Finally, Robert W. Baird dropped their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus target price of $77.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.